Zoetis Inc. (NYSE:ZTS) Position Boosted by First Bank & Trust

First Bank & Trust lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 0.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 10,002 shares of the company’s stock after purchasing an additional 83 shares during the period. First Bank & Trust’s holdings in Zoetis were worth $1,954,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of ZTS. Sarasin & Partners LLP lifted its position in shares of Zoetis by 546.3% during the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock worth $390,682,000 after purchasing an additional 1,904,899 shares during the last quarter. Swedbank AB bought a new position in Zoetis in the first quarter worth about $210,815,000. International Assets Investment Management LLC lifted its holdings in Zoetis by 41,235.7% in the third quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock worth $183,652,000 after acquiring an additional 937,700 shares during the last quarter. Marshall Wace LLP lifted its holdings in Zoetis by 7,608.6% in the second quarter. Marshall Wace LLP now owns 835,684 shares of the company’s stock worth $144,874,000 after acquiring an additional 824,843 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Zoetis by 1.0% in the first quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock worth $6,895,235,000 after acquiring an additional 414,605 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Zoetis stock traded down $1.49 during mid-day trading on Friday, hitting $180.01. The company’s stock had a trading volume of 2,623,220 shares, compared to its average volume of 2,517,962. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The stock has a market capitalization of $82.14 billion, a P/E ratio of 34.68, a P/E/G ratio of 2.94 and a beta of 0.89. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The stock’s fifty day moving average price is $189.10 and its two-hundred day moving average price is $177.71.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.07. The firm had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.41 earnings per share. Research analysts forecast that Zoetis Inc. will post 5.83 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be paid a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a yield of 0.96%. The ex-dividend date is Thursday, October 31st. Zoetis’s dividend payout ratio is 33.14%.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Piper Sandler raised their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. BTIG Research raised their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. JPMorgan Chase & Co. raised their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, Stifel Nicolaus raised their price target on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.